Blood Purification

Original Paper

Cytokine Clearances in Critically Ill Patients on Continuous Renal Replacement Therapy

Chen L.-X.a · Demirjian S.b · Udani S.M.c · Trevino S.A.c · Murray P.T.d,e · Koyner J.L.c

Author affiliations

aDepartment of Medicine, Section of Transplant Nephrology, Division of Nephrology, University of California, Sacramento, CA, USA
bDepartment of Nephrology and Hypertension, Department of Medicine, Cleveland Clinic, Cleveland, OH, USA
cDepartment of Medicine, Section of Nephrology, University of Chicago, Chicago, IL, USA
dConsultant in Nephrology, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
eClinical Pharmacology, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland

Keywords: Acute kidney injuryContinuous renal replacement therapyCytokinesInterleukin-1betaInterleukin-6Tumor necrosis factor

Related Articles for ""
Blood Purif 2018;46:315–322
https://doi.org/10.1159/000492025

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 12, 2018
Accepted: July 09, 2018
Published online: August 14, 2018
Issue release date: October 2018

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 6

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Background/Aims: We sought to quantify any differences in cytokine clearance between continuous venovenous hemofiltration (CVVH-convective) compared to continuous venovenous hemodialysis (CVVHD-diffusive). Methods: We conducted a 20 patient, multicenter, prospective, open-label randomized trial (CVVH or CVVHD) at continuous renal ­replacement therapy (CRRT) initiation. Blood, urine, and effluent were collected at 0, 4, 24, and 48 h after initiation of CRRT. Serum electrolytes, cytokines levels, and clearances were measured. Cytokines studies included IL-1β, IL-1RA, IL-6, IL-10, and TNFα. Results: We randomized 20 patients to receive CRRT. After 4 h of CRRT there was no difference in total cytokine levels or change in cytokine concentrations across the 2 groups. With the exception of IL-1 RA, all cytokines levels decreased across patient groups regardless of modality. There was no significant difference in cytokine concentration across CRRT modality for any time point. Conclusion: Within the first 4 h of CRRT initiation, there is no significant difference between cytokine or solute clearance between CVVH and CVVHD.

© 2018 S. Karger AG, Basel



Related Articles:

References

  1. Lee DW, Faubel S, Edelstein CL: Cytokines in acute kidney injury (AKI). Clin Nephrol 2011; 76: 165–173.
  2. Opal SM, DePalo VA: Anti-inflammatory cytokines. Chest 2000; 117: 1162–1172.
  3. Kellum JA, Bellomo R, Ronco C: Kidney attack. JAMA 2012; 307: 2265–2266.
  4. Schulte W, Bernhagen J, Bucala R: Cytokines in sepsis: potent immunoregulators and potential therapeutic targets – an updated ciew. Mediators Inflamm 2013; 2013: 165974.
  5. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, et al: Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357–1365.
  6. Murugan R, Wen X, Shah N, Lee M, Kong L, Pike F, et al: Plasma inflammatory and apoptosis markers are associated with dialysis dependence and death among critically ill patients receiving renal replacement therapy. Nephrol Dial Transplant 2014; 29: 1854–1864.
  7. McCullough PA, Bouchard J, Waikar SS, Siew ED, Endre ZH, Goldstein SL, et al: Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 5–12.
  8. Hoste EA, Kellum JA, Katz NM, Rosner MH, Haase M, Ronco C: Epidemiology of acute kidney injury. Contrib Nephrol 2010; 165: 1–8.
  9. Ronco C, Kellum JA, Haase M: Subclinical AKI is still AKI. Crit Care 2012; 16: 313.
  10. Jacobs P, Glorieux G, Vanholder R: Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. Nephrol Dial Transplant 2004; 19(suppl 5):v41–v45.
  11. Dahaba AA, Elawady GA, Rehak PH, List WF: Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 2002; 3: 269–274.
  12. Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, et al: Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004; 43: 444–453.
  13. Morgera S, Klonower D , Rocktaschel J, Haase M, Priem F, Ziemer S, Wegner B, et al: TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients? Nephrol Dial Transplant 2003; 18: 1361–1369.
  14. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR: Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 1998; 26: 1995–2000.
  15. Peng Y, Yuan Z, Li H: Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns 2005; 31: 623–628.
  16. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846–853.
  17. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445–2452.
  18. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al: Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41: 975–984.
  19. Iba T, Fowler L: Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care 2017; 5: 40.
  20. Ricci Z, Ronco C, Bachetoni A, D’Amico G, Rossi S, Alessandri E, et al: Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67.
  21. Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, et al: Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 2016; 20: 318.
  22. Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, et al: Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care 2016; 20: 283.
  23. Ronco C, Bellomo R: Continuous renal replacement therapy: evolution in technology and current nomenclature. Kidney Int Suppl 1998; 66:S160–S164.
  24. Bellomo R, Ronco C, Mehta RL: Nomenclature for continuous renal replacement therapies. Am J Kidney Dis 1996; 28:S2–S7.
  25. Cole L, Bellomo R, Davenport P, Tipping P, Ronco C: Cytokine removal during continuous renal replacement therapy: an ex vivo comparison of convection and diffusion. Int J Artif Organs 2004; 27: 388–397.
  26. Wald R, Friedrich JO, Bagshaw SM, Burns KE, Garg AX, Hladunewich MA, et al: Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) – a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project. Crit Care 2012; 16:R205.
  27. Ronco C, Ricci Z, De Backer D, Kellum JA, Taccone FS, Joannidis M, et al: Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 2015; 19: 146.
  28. Murugan R, Wen X, Keener C, Pike F, Palevsky PM, Unruh M, et al: Associations between intensity of RRT, inflammatory mediators, and outcomes. Clin J Am Soc Nephrol 2015; 10: 926–933.
  29. Servillo G, Vargas M, Pastore A, Procino A, Iannuzzi M, Capuano A, et al: Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data. BioMed Res Int 2013; 2013: 108951.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 12, 2018
Accepted: July 09, 2018
Published online: August 14, 2018
Issue release date: October 2018

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 6

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2018, Vol.46, No. 4

October 2018

Article

Recommend This
TOP